TY - JOUR AU - Ilie, Marius AU - Hofman, Paul PY - 2017 TI - Atezolizumab in advanced non-small cell lung cancer JF - Journal of Thoracic Disease; Vol 9, No 10 (October 31, 2017): Journal of Thoracic Disease Y2 - 2017 KW - N2 - Atezolizumab (Tecentriq ® , MPDL3280A, Genentech, CA, USA) is a humanized IgG1 antagonist antibody to PD-L1 engineered to avoid antibody-dependent cell-mediated cytotoxicity of activated T cells that may express PD-L1 (1). It blocks directly the interaction between the PD-L1 and PD-1/B7.1 receptors activation complex, hence it activates the tumor-specific immune response, and induces tumor cell killing (1). UR - https://jtd.amegroups.org/article/view/15955